Log in to search using one of your social media accounts:

 

Baxter inks partnership deal with International Society of Nephrology

Baxter (NYSE:BAX) said today it inked a partnership deal with the International Society of Nephrology looking to advance awareness and therapy for patients with chronic kidney disease, primarily in low and middle-income countries where the disease is growing the fastest. In the collaborative partnership , Deerfield, Ill.-based Baxter and the ISN will look to support further therapy research and education about chronic kidney disease, while also looking to develop better care models at lower costs. “ISN and Baxter’s collaboration aims to address the urgent and growing challenge kidney disease is causing healthcare systems in providing quality care to patients globally. Our organization is dedicated to connecting communities to collaborate on supporting greater access to care models that focus on how to improve prevention, diagnosis and treatment of kidney disease,” Dr. David Harris of Australia’s University of Sydney said in a prepared statement. “It is Baxter’s goal to make renal care available to people in need, while driving better outcomes through new standards. Our partnership with ISN moves us closer to this goal by combining Baxter’s clinical and innovation expertise with ISN’s educational and research expertise in a truly transformative approach to increasing access to care worldwide,” Baxter renal care GM Laura Angelini said in a press release. In March, Baxter said it that it closed the $153 million acquisiti...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Baxter Source Type: news

Related Links:

Publication date: Available online 18 May 2018 Source:American Journal of Kidney Diseases Author(s): Victoria Títoff, Heather N. Moury, Igor B. Títoff, Kevin M. Kelly There are 2 major categories of patients with seizures and chronic kidney disease (CKD): patients who develop acute symptomatic seizures in the setting of CKD and patients with epilepsy who at some point develop CKD. The incidence of uremic seizures with kidney failure is ∼10%. These seizures are often nonconvulsive and may mimic uremic encephalopathy. Recognition and management of such situations may be challenging for treating physicians ...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Conclusions In people with diabetes with reduced eGFRs, the absence of albuminuria or proteinuria is common and carries a much lower risk for ESKD, CKD progression, or rapid decline in eGFR compared with those with albuminuria or proteinuria. The rate of eGFR decline in normoalbuminuric CKD was similar to that reported for the general diabetic population.
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Conclusions In a longitudinal study of patients with CKD who subsequently initiated dialysis therapy, LVEF and LVESV worsened and were significantly associated with greater risk for postdialysis mortality. There may be opportunities for intervention during this transition period to improve outcomes.
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Protein-Energy Wasting (PEW) is a pathological condition of renal patients with advanced Chronic Kidney Disease characterized by a progressive reduction of energy and protein assets. Nutritional status assessment, especially for what concerns muscle mass, is essential for both the identification of patients at risk for the development of PEW, as well as monitoring the effects of nutritional interventions. Ultrasound methods are easily applicable at the bedside for quantitative assessment of skeletal muscle.
Source: Clinical Nutrition - Category: Nutrition Authors: Tags: Original article Source Type: research
In this issue of Journal of Neuro-Ophthalmology, M. Tariq Bhatti, MD and Mark L. Moster, MD will discuss the following 6 articles: Nazarian S, Hansford R, Rahsepar AA, Weltin V, McVeigh D, Gucuk Ipek E, Kwan A, Berger RD, Calkins H, Lardo AC, Kraut MA, Kamel IR, Zimmerman SL, Halperin HR. Safety of magnetic resonance imaging in patients with cardiac devices. N Engl J Med. 2017;377:2555–2564.Martin DR, Kalb B, Mittal A, Salman K, Vedantham S, Mittal PK. No incidence of nephrogenic systemic fibrosis after gadobenate dimeglumine administration in patients undergoing dialysis or those with severe chronic kidney disease....
Source: Journal of Neuro-Ophthalmology - Category: Opthalmology Tags: Literature Commentary: PDF Only Source Type: research
Source: CDC Preventing Chronic Disease - Category: International Medicine & Public Health Tags: Public Health Source Type: news
Iron-deficiency anemia (IDA) is undertreated in patients with chronic inflammatory conditions including chronic kidney disease (CKD) and heart failure (HF). Progressive inflammation and reduced iron transport associated with CKD and HF may reduce the efficacy of oral iron therapy. Oral ferric citrate improves anemia markers in CKD, but its effects in patients with CKD and concomitant HF have not been described. Patients with CKD not on dialysis and IDA from a phase 2 and 3 trial were treated with ferric citrate (n  = 190) or placebo (n = 188); patients with HF were identified from medical histories.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Conclusions Changes in renal biomarkers suggest mild acute kidney injury and reduced kidney function during a single bout of endurance cycling in the heat, without influence from moderate ibuprofen ingestion.
Source: Journal of Science and Medicine in Sport - Category: Sports Medicine Source Type: research
Conclusions Females and patients over 50 seem to be more vulnerable to renal impairment. Potentially modifiable risk factors and exposure to tenofovir disoproxil-fumarate or ritonavir-boosted protease-inhibitors are present even in earlier stages of chronic kidney dysfunction. It remains to be determined whether early interventions including antiretroviral therapy changes (tenofovir alafenamide, cobicistat) or improving comorbidities management will improve the course of chronic kidney disease.
Source: The Brazilian Journal of Infectious Diseases - Category: Infectious Diseases Source Type: research
Conditions:   Bone Disorder;   Chronic Kidney Diseases Intervention:   Other: Measure of etecalcetide on osteoclastic biology Sponsor:   Hospices Civils de Lyon Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Australia Health | Chronic Kidney Disease | Education | Mergers and Aquisitions | Partnerships | Universities & Medical Training | Urology & Nephrology